Age-related sex differences in the outcomes of patients with hypertrophic cardiomyopathy
Source : https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0264580
Background We aimed to clarify the sex differences in various cardiovascular and non-cardiovascular outcomes, and to investigate whether sex differences in outcomes are affected by age in hypertrophic cardiomyopathy (HCM)....
Conclusions: Women with HCM have worse cardiovascular prognosis than men, driven by higher cardiovascular mortality and HF events. The negative impact of female sex on cardiac function and cardiovascular outcome became prominent at age ≥60 years, suggesting age-related sex differences in the prognosis of HCM.
Conclusions: Women with HCM...
Share
Clinical implications of left atrial reverse remodelling after cardiac resynchronization therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35213709/
doi: 10.1093/ehjci/jeac042. Online ahead of print. 1 Department of Cardiology, Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, The Netherlands. 2 Department of Cardiology, Jessa Hospital, 3500 Hasselt, Belgium....
Conclusions: Patients with complete reverse remodelling have a lower mortality risk than those showing incomplete or no significant reverse remodelling. The use of integrated LA and LV deformation imaging may improve risk-stratification of CRT recipients.
Share
SGLT-2 Inhibitor Use in Heart Failure: A Review for Nurses - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35212658/
1 Clinical Pharmacy Department, Methodist University Hospital, Memphis, Tennessee (Drs March, Lukas, and Cave); University of Tennessee Health Science Center, College of Pharmacy, Memphis (Drs March, Lukas, and Cave); and...
Relevance: The purpose of this review is to summarize available literature focusing on the use of the SGLT-2 inhibitors as adjunctive therapy in heart failure, as well as evaluate mechanisms for heart failure benefit, adverse effects, and practical considerations for using these agents in the clinical setting.
Share
Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study
Source : https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0262831
Patients with type 2 diabetes who have cardiovascular disease and are receiving empagliflozin have a lower rate of primary composite cardiovascular outcomes. In contrast, glimepiride increases cardiovascular hospitalization when combined...
Conclusion/Relevance: Hence, although empagliflozin did not improve endothelial function compared with glimepiride for patients with type 2 diabetes, it did decrease body fluid volumes. Thus, the coronary-protective effect of empagliflozin is not derived from endothelial function protection, but rather from heart failure risk reduction.
Share
The effect of empagliflozin on p wave peak time and other p wave parameters in patients with diabetes mellitus
Source : https://onlinelibrary.wiley.com/doi/10.1111/pace.14463
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between...
Conclusion: We found shortening of PWPT, PWdis, and PWD as reflections of improvements in LA volume and LV diastolic function on ECG after empagliflozin treatment.
Share
-
Heart Failure Connect4yrKey Points • Source: Pacing and Clinical Electrophysiology • Conclusions/Relevance: “We found shortening of PWPT, PWdis, and PWD as reflections of improvements in LA volume and LV diastolic function on ECG after empagliflozin Show More